share_log

Chardan Capital Maintains Buy on Axcella Health, Lowers Price Target to $5

Chardan Capital Maintains Buy on Axcella Health, Lowers Price Target to $5

Chardan Capital維持對Axcella Health的買入,將目標股價下調至5美元
Benzinga Real-time News ·  2022/11/02 10:36

Chardan Capital analyst Keay Nakae maintains Axcella Health (NASDAQ:AXLA) with a Buy and lowers the price target from $7 to $5.

Chardan Capital分析師Keay Nakae維持Axcella Health(納斯達克股票代碼:AXLA)的買入,並將目標股價從7美元下調至5美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論